Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide is a synthetic small molecule compound featuring a carboxamidine (guanidino) group attached to a benzyl moiety, with additional cyclohexyl and pyrrolidine carboxamide functionalities. The structure suggests it may act as an inhibitor of serine proteases, particularly thrombin or related coagulation factors, due to the presence of the guanidino group which is characteristic of direct thrombin inhibitors. However, there is no direct evidence in the provided sources confirming its clinical use or specific target. It appears in chemical and patent literature as a research compound but does not have established pharmaceutical branding or approval status[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide.